Truncus arteriosus (TA)
Methodology & AI Transparency ⓘ
Truncus arteriosus (TA) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Truncus arteriosus (TA) (ICD-10-CM Q20.0), Children's & Adolescent Health protocols prioritize immunization schedule review [Truncus arteriosus (TA) Q20.0] paired with baseline and interval WHO / CDC in Truncus arteriosus (TA) (Q20.0: Age-Adjusted Growth Percentiles) assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code Q20.0 categorizes Truncus arteriosus (TA) under Children's & Adolescent Health.
- 3 Typical cash cost range: Differential triage of Truncus arteriosus (TA) (Q20.0) utilizes immunization schedule review [Truncus arteriosus (TA) Q20.0].
- 4 Top reported side effects / signs: Objective lab/clinical target for Truncus arteriosus (TA): WHO / CDC in Truncus arteriosus (TA) (Q20.0: Age-Adjusted Growth Percentiles) (Consistent personal growth curve tracking (Q20.0)) and Pediatric Hemoglobin & in Truncus arteriosus (TA) (Q20.0: Lead Screen).
Ask our AI Specialists anything about Truncus arteriosus (TA)
What Is Truncus arteriosus (TA)?
For patients presenting with Truncus arteriosus (TA) (ICD-10-CM Q20.0), Children's & Adolescent Health protocols prioritize immunization schedule review [Truncus arteriosus (TA) Q20.0] paired with baseline and interval WHO / CDC in Truncus arteriosus (TA) (Q20.0: Age-Adjusted Growth Percentiles) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Truncus arteriosus (TA) (ICD-10 Q20.0) is driven by developing pediatric mucosal in Truncus arteriosus (TA) (Q20.0: immunity); specialists in Children's & Adolescent Health monitor Pediatric Hemoglobin & in Truncus arteriosus (TA) (Q20.0: Lead Screen) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Truncus arteriosus (TA) (Q20.0): acute childhood fever, in Truncus arteriosus (TA) (Q20.0: barking cough, wheezing,)
- • Secondary Truncus arteriosus (TA) clinical sign: developmental milestone questions in Truncus arteriosus (TA) (Q20.0: across speech, motor)
- • Symptom flares in Truncus arteriosus (TA) correlating with WHO / CDC in Truncus arteriosus (TA) (Q20.0: Age-Adjusted Growth Percentiles) deviation outside Consistent personal growth curve tracking (Q20.0)
- • Functional pediatrics impact requiring immunization schedule review [Truncus arteriosus (TA) Q20.0] evaluation (Q20.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Truncus arteriosus (TA) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q20.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: WHO / CDC in Truncus arteriosus (TA) (Q20.0: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (Q20.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Truncus arteriosus (TA) (Q20.0: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q20.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Truncus arteriosus (TA)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Ibuprofen Lysine Neoprofen • RxCUI 637197 | Nonsteroidal Anti-inflammatory Drug | 90% | $0.0345 | $ 9.90 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Truncus arteriosus (TA))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Lubiprostone for children Functional Constipation: Randomized, Controlled,: What a 202-Participant Study Found Lubiprostone did not demonstrate statistically significant effectiveness over placebo in children and adolescents with PFC but did demonstrate a safety profile similar to that in adults. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2022-03-15 • Phase III Randomized Trial | N = 202 | 88/100 | PMID 33838349 ↗ |
| Can This Approach Help? Inside the Latest Research on Macitentan in children lung Arterial high blood pressure (TOMORROW): A Randomized TOMORROW was a novel study assessing PK and the long-term real-world benefits and safety of macitentan vs SoC in children PAH. The Journal of pediatrics • 2026-06-15 • Phase III Randomized Trial | N = 148 | 82/100 | PMID 41796854 ↗ |
| Can This Approach Help? Inside the Latest Research on Growth Hormone Deficiency (GHD) Reversal Trial: effect on final height of This new care pathway would also prevent children from having unnecessary daily GH injections and consequent exposure to potential adverse effects. Trials • 2023-08-21 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37605233 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of attractive targeted sugar bait stations against malaria in Western Two ATSB stations deployed per eligible structure for two consecutive transmission seasons did not result in a statistically significant reduction in clinical malaria incidence among children aged 1-14 years or in P. Malaria journal • 2024-11-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39548456 ↗ |
Truncus arteriosus (TA) Patient Community & “People Like Me” Threads
Filter Truncus arteriosus (TA) community threads and patient logs by age, biological sex, dosage, and treatment duration.